LPCN 1021
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hypogonadism, Male
Conditions
Hypogonadism, Male
Trial Timeline
Dec 1, 2016 → Jul 1, 2017
NCT ID
NCT03242590About LPCN 1021
LPCN 1021 is a phase 3 stage product being developed by Lipocine for Hypogonadism, Male. The current trial status is completed. This product is registered under clinical trial identifier NCT03242590. Target conditions include Hypogonadism, Male.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03868059 | Phase 3 | Completed |
| NCT03242408 | Phase 3 | Completed |
| NCT03242590 | Phase 3 | Completed |
Competing Products
20 competing products in Hypogonadism, Male